Showing 1,041 - 1,060 results of 13,729 for search '(( significantly increased decrease ) OR ( significant ((small decrease) OR (greater decrease)) ))*', query time: 0.50s Refine Results
  1. 1041
  2. 1042
  3. 1043
  4. 1044

    PTEN KD increases chromatin accessibility. by Ahmed H. Ghobashi (12705573)

    Published 2024
    “…Red dots indicate peaks with significantly increased or decreased accessibility with Log2 FC > |0.5|. …”
  5. 1045
  6. 1046
  7. 1047
  8. 1048
  9. 1049
  10. 1050

    Summary of study eligibility criteria. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  11. 1051

    Summary of study participation and feasibility. by Biban Gill (1473337)

    Published 2025
    “…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”
  12. 1052
  13. 1053
  14. 1054
  15. 1055
  16. 1056
  17. 1057
  18. 1058
  19. 1059
  20. 1060